Know Cancer

forgot password

Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

18 Years
Open (Enrolling)
Lynch Syndrome, Colorectal Cancer

Thank you

Trial Information

Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

Lynch Syndrome:

Lynch syndrome (LS), previously known as "hereditary non-polyposis colorectal cancer", is a
hereditary cancer syndrome that causes the majority of hereditary CRC and approximately 3%
of all CRC. LS significantly increases the risk for an individual to develop CRC during
their lifetime. Individuals with LS also have an increased risk to develop extracolonic
cancers, including endometrial, gastric, ovarian, upper urinary tract, small bowel, biliary
tract, CNS, and certain types of skin cancer. Tumor studies, including microsatellite
instability (MSI) testing and immunohistochemical (IHC) analysis, provide information
regarding characteristic features of LS-associated tumors and can help target genetic
testing. Given the hereditary nature of this syndrome, screening all patients who are newly
diagnosed with CRC for LS can identify additional individuals who are at high-risk of
developing cancer.

Study Aims:

By developing a CRC research infrastructure within the state of Ohio, the OCCPI will achieve
the following specific aims:

- Establish and implement a statewide universal screening protocol for LS.

- Elucidate the prevalence of hereditary CRC in Ohio.

- Provide screening recommendations for high-risk individuals with CRC and their
families, as well as local access to genetic counseling.

- Create a CRC biorepository for future research on the etiology of CRC from the leftover
samples of the CRC patients, as well as samples from their relatives.

With the successful implementation of the OCCPI, knowledge will be gained that will
facilitate the adoption of a universal screening protocol for LS in Ohio and the creation of
a statewide CRC biorepository to be used for additional studies on cancer risks, prevention,
screening, treatment and survivorship.

Study Procedures for CRC and EC participants:

- You will be asked to donate 2-3 tablespoons of blood.

- A small piece of your colorectal or endometrial tumor will be obtained from the
hospital where you had your surgery.

- You will be asked to contribute your leftover samples (tumor and blood) to the OCCPI
biorepository (sample bank) for help with future research. Additionally, CRC
participants will be asked to donate a saliva sample to the OCCPI biorepository. The
samples will be kept securely in a lab at OSU. Before your samples can be used for
research, the people doing the research must get specific approval from the OCCPI
Steering Committee and possibly the Institutional Review Board (IRB) of OSU. The IRB is
responsible for protecting the participants involved in research studies and making
sure all research is done in a safe and ethical manner.

- You will be asked to complete a questionnaire which will ask about your age, medical
history, family history, lifestyle factors and environmental exposures. It should take
about one hour to complete the questionnaire and you can complete it from home.

- We will test your tumor for features of LS (MSI, IHC, methylation).

- If your tumor shows features of LS or if you were diagnosed under age 50 or have a
family history of CRC or endometrial cancer, we will test your blood for the genes that
cause LS, as well as other genes that can cause hereditary cancer.

- If you are found to have LS or another type of hereditary cancer, you will be offered
free genetic counseling.

- If you are found to have LS, your at-risk relatives will be offered free genetic
counseling and genetic testing.

Study Procedures for first-degree relatives (FDR) of the CRC participants:

The FDRs of all of the CRC study participants will be given the opportunity to contribute to
the biorepository for future research.

- Family Member Consent for Contact forms will be provided to the CRC participant at the
time of their enrollment for them to distribute to all of their FDRs (parents, siblings
and adult children ≥ 25 years). The FDRs will mail the signed form to OSU.

- After obtaining permission to contact the FDRs, OSU will mail them the biorepository
consent form and saliva kit to return to the OCCPI biorepository.

- The FDRs of the CRC study participants will also be invited to complete the baseline

Length of study:

- The LS tumor screening portion of the OCCPI will take 1-4 months.

- If applicable, genetic testing results should be ready in an additional 3-6 months.

- Overall, your participation in the LS screening portion of the OCCPI is expected to
take about 1 year. Most of this time will be spent waiting for results. Your active
involvement will take about 15 minutes on the day that you provide consent and about 60
minutes when you complete the questionnaire from home.

Inclusion Criteria:

1. Newly diagnosed with colorectal adenocarcinoma (all stages) and have a resection at
any hospital in Ohio between 1/1/2013 and 9/30/2014.

- For individuals who have neoadjuvant treatment and show a complete response at
resection, the tumor screening will be attempted on their original biopsy (even
if it occurred in 2012) as long as their resection occurred between 1/1/2013 and

- Many individuals with stage IV CRC will not have a resection; therefore, the
tumor screening will be attempted on their original colon biopsy as long as
their primary diagnosis occurred between 1/1/2013 and 9/30/2014. If only
metastatic CRC is available on a biopsy (liver or lymph node metastases), tumor
screening will be attempted on the metastatic tissue.

2. Newly diagnosed with endometrial cancer (any histology except sarcoma) and have a
resection between 1/1/2013 and 9/30/2014 at OSU only.

3. All at-risk relatives of the participants found to have LS.

4. First-degree relatives (parents, siblings and adult children ≥ 25 years of age) of
the CRC participants who do not have LS.

Exclusion Criteria:

1. Prisoners.

2. Individuals who are under the age of 18.

3. Individuals must have a primary colorectal or endometrial cancer, not a recurrence of
a previous colorectal or endometrial cancer.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Outcome Measure:

Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients

Outcome Description:

Through tumor testing for Lynch syndrome and follow-up genetic testing for all patients with abnormal tumor testing and select patients with normal tumor testing (those diagnosed under age 50 and those at 50 or over with a first degree relative with colorectal or endometrial cancer).

Outcome Time Frame:

18 months (initial assessment)

Safety Issue:


Principal Investigator

Heather Hampel, MS, CGC

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ohio State University Comprehensive Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2012

Completion Date:

September 2017

Related Keywords:

  • Lynch Syndrome
  • Colorectal Cancer
  • colorectal cancer
  • colon cancer
  • rectal cancer
  • endometrial cancer
  • Lynch syndrome
  • Ohio colon cancer study
  • OSU colon study
  • Colorectal Neoplasms
  • Colorectal Neoplasms, Hereditary Nonpolyposis



Akron General Medical Center Akron, Ohio  44302
Mount Carmel West Hospital Columbus, Ohio  43222
Grady Memorial Hospital Delaware, Ohio  43015
Mercy Medical Center Springfield, Ohio  45504
Miami Valley Hospital Dayton, Ohio  45409
Knox Community Hospital Mount Vernon, Ohio  43050
Fairview Hospital Cleveland, Ohio  44111
HillCrest Hospital Mayfield Heights, Ohio  44124
Cleveland Clinic Cleveland, Ohio  44195
Riverside Methodist Hospital Columbus, Ohio  43214
Licking Memorial Hospital Newark, Ohio  43055-2899
Grant Medical Center Columbus, Ohio  43215
Kettering Medical Center Kettering, Ohio  45429
Marietta Memorial Hospital Marietta, Ohio  45750
Upper Valley Medical Center Troy, Ohio  45373
Aultman Hospital Canton, Ohio  44710
The Christ Hospital Cincinnati, Ohio  45219
Mount Carmel East Hospital Columbus, Ohio  43213
Southern Ohio Medical Center Portsmouth, Ohio  45662
Metrohealth Cleveland, Ohio  44109
Springfield Regional Medical Center Springfield, Ohio  45505
Akron City/St. Thomas Hospital (Summa Health System) Akron, Ohio  44309
Summa Barberton (Summa Health System) Barberton, Ohio  44203
Adena Health System ChillIcothe, Ohio  45601
Good Samaritan Hospital (TriHealth) Cincinnati, Ohio  45220
University Hospital (University of Cincinnati) Cincinnati, Ohio  45267
Bethesda North Hospital (TriHealth) Cincinnati, Ohio  45242
Doctors Hospital West Columbus, Ohio  43228
Summa Western Reserve (Summa Health System) Cuyahoga Falls, Ohio  44223
Good Samaritan Hospital Dayton Dayton, Ohio  45415
Union Hospital Dover, Ohio  44622
Blanchard Valley Health System Findlay, Ohio  45840
Marymount Hospital Garfield Heights, Ohio  44124
Atrium Medical Center Middletown, Ohio  45005
Robinson Memorial (Summa Health System) Ravenna, Ohio  44266
Flower Hospital (ProMedica Health System) Sylvania, Ohio  43560
Toledo Hospital (Promedica Health System) Toledo, Ohio  43606
West Chester Hospital West Chester, Ohio  45069
Mount Carmel St. Ann's Hospital Westerville, Ohio  43081
Genesis Cancer Care Center (Genesis Healthcare System) Zanesville, Ohio  43701